

ELISA KRILL-JACKSON M.D., F.A.C.P.

**WORK:**

Mount Sinai Comprehensive Cancer Center  
4306 Alton Road  
Miami Beach, Florida 33140  
(305) 535-3300  
(305) 535-3356 Fax

**PRACTICE:** Mount Sinai Comprehensive Cancer Center  
Hematology-Oncology, 7/96-present

**EDUCATION:**

Fellowship: University of Miami  
Miami, Florida  
Hematology-Oncology, 1994-1996

New England Medical Center  
Boston, Massachusetts  
Hematology-Oncology, 1993-1994

Residency: Brigham and Women's Hospital  
Boston, Massachusetts  
Internal Medicine, 1990-1993

Medical School: University of Michigan Medical School  
Ann Arbor, Michigan  
M.D. 1990  
Graduation with distinction  
Hewlett-Packard Award, top five students in graduating class  
Dean's Award, top rank in first year class  
Alpha Omega Alpha, third year; vice president, fourth year  
Eli G. Rochelson Memorial Award, outstanding performance in pulmonary medicine  
MacGregor Scholarship, 1986-1990

College: Yale University  
New Haven, Connecticut  
Bachelor of Arts, English, 1986  
Summa cum laude  
Graduation with distinction in the English major  
Phi Beta Kappa, junior year

**PUBLICATIONS:**

Alternate Putrescine Metabolites, *Analytical biochemistry*, 148, 1985.

Long-Term Survival in Hodgkin's Disease, *Cancer Journal Scientific American*, 1995.

Second Malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome, *Blood* 87:3625-3632, 1996.

High dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) transplantation in inflammatory breast cancer, *ASCO Meeting Abstracts* 1996: 953.

The faces of mast cell disease: bone marrow infiltrates in 3 patients with systemic mastocytosis, *Annals of Diagnostic Pathology* 9, 2003: 81-85.

Preliminary results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC), *J Clin Oncol* 23 No. 16S, 2005: 876.

Updated results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC), *J Clin Oncol* 24 No. 18S, 2006: 10685.

Identification of a recurring BRCA1 mutation in Bahamian women with breast cancer, San Antonio Breast Conference Meeting Abstracts 2007: 2040.

A Phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): Interim safety results, *J Clin Oncol* 26: 2008: (May 20 suppl; abstr 1095).

Preliminary results of a phase 2 randomized study of paclitaxel and bevacizumab ± gemcitabine as first line treatment for metastatic breast cancer, *J Clin Oncol* 27:15s, 2009 (suppl; abstr 1089)

High Frequency of BRCA1 Founder Mutations in the Bahamas, San Antonio Breast Conference Meeting Abstracts 2009:4078.

**ASSOCIATIONS:**

Member, American Society of Hematology  
Member, American Society of Clinical Oncology  
Fellow, American College of Physicians  
Member NSABP Breast Committee, 2001-present

**CERTIFICATIONS:**

American Board of Internal Medicine, 1993  
American Board of Hematology, 1996 and 2006  
American Board of Oncology, 1997 and 2007